Y-mAbs Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Y-mAbs Therapeutics

10/08/2023 22:01

* Y-mAbs Therapeutics Inc  YMAB.OQ  reported a quarterly
adjusted
loss of 14 cents​​ per share for the quarter ended in June. The
mean expectation of seven analysts for the quarter was for a
loss of 24 cents per share.
    * Revenue rose 92.2% to $20.75 million from a year ago;
analysts
expected $20.35 million. 
    * Y-mAbs Therapeutics Inc's reported EPS for the quarter was
a
loss of 14 cents​.
    * The mean earnings estimate of analysts had risen by
about 11% in
the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Y-mAbs Therapeutics Inc shares had fallen by 14.0% this
quarter and gained 19.7% so far this year.
    * The company reported a quarterly loss of $6.3 million.
    * Wall Street's median 12-month price target for Y-mAbs
Therapeutics Inc is $12.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 09:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.24          -0.14          Beat
 Mar. 31 2023      -0.32          -0.15          Beat
 Dec. 31 2022      -0.46          0.03           Beat
 Sep. 30 2022      -0.71          -0.63          Beat